HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

The Foreign Secretary gave a speech at The Africa Debate on 2 July 2025. Ladies and Gentleman, Friends.It's a great, great ...

A team of leading infectious disease scientists from academia and industry have been awarded £17.9 million to identify new ...

A team of leading infectious disease scientists from academia and industry have been awarded £17.9 million to identify new ...

BactiVac showcases expertise at the World Vaccine Congress 2025, championing global equity and innovation in bacterial vaccine development.

Even with the HIV prevention waters now dominated by Gilead Science’s Yeztugo (lenacapavir), Merck & Co. is not afraid to swim deeper in. | Even with the HIV prevention waters now dominated by Gilead ...

US and European stock markets stalled or trimmed gains on Friday after a bullish week buoyed by US data and upbeat company ...

The sharpest fall was seen at the brand level, with only 14 brands advertising during the 2025 final, a drastic drop from 70 ...

Merck MRK recently launched two late-stage clinical studies to evaluate MK-8527, its investigational once-monthly oral pill for HIV pre-exposure prophylaxis (PrEP). The EXPrESSIVE-11 study, which ...

The investigational oral pre-exposure prophylaxis (PrEP) agent MK-8527 showed a similar, well-tolerated safety profile to ...

A team of infectious disease scientists have been awarded £17.9m to identify new drugs to treat fungal infections.